![\"jimenez\"](\"http:\/\/s.wsj.net\/media\/jimenez_D_20100126084507.jpg\")
New Novartis chief Joe Jimenez (right) is looking at beefing up some business segments with acquisitions, but has nothing in mind as big as its $39.3 billion plan to buy the rest of eye-care company Alcon.<\/p>\nNew Novartis chief Joe Jimenez (right) is looking at beefing up some business segments with acquisitions, but has nothing in mind as big as its $39.3 billion plan to buy the rest of eye-care company Alcon.<\/p>\n
\u0093We may go for smaller, bolt-on acquisitions to help build scale in vaccines, generics and consumer health, but we will not go for one of the same size and scale as Alcon for the foreseeable future,” Jimenez said at the Novartis annual meeting, according to Reuters<\/a>. Jimenez, who succeeded Dan Vasella<\/a> as Novartis CEO this month, didn\u0092t comment on the plan for buying the shares<\/a> it doesn’t already own in Alcon. <\/p>\n At the meeting in Basel, 95% of the Swiss company\u0092s shareholders also backed the introduction of a “say on pay” provision that will give holders a vote on executive and board-member remuneration issues at least every third year but not on individual salaries. Dow Jones Newswires<\/a> reports on that angle.<\/p>\n Vasella, who is one of the highest-paid managers in Switzerland and received around $18.6 million last year in stock and options, has been repeatedly criticized for his remuneration packages, DJ adds. He remains chairman of Novartis.<\/p>\n As for Novartis overall, Reuters notes that its shares trade at a premium to GlaxoSmithKline, AstraZeneca and Sanofi-Aventis thanks to promising new drugs like multiple sclerosis pill Gilenia. “Novartis has better prospects than many of its European competitors, except Roche, to overcome the challenges posed by the patent cliff in the period between 2010 and 2012 …,” it quotes an analyst as saying.<\/p>\n Photo: Associated Press<\/p>\n New Novartis chief Joe Jimenez (right) is looking at beefing up some business segments with acquisitions, but has nothing in mind as big as its $39.3 billion plan to buy the rest of eye-care company Alcon. \u0093We may go for smaller, bolt-on acquisitions to help build scale in vaccines, generics and consumer health, but we […]<\/p>\n","protected":false},"author":792,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-367893","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/367893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/792"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=367893"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/367893\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=367893"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=367893"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=367893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}<\/img><\/a>
\n<\/img><\/a><\/p>\n
\n<\/img><\/a>
<\/img><\/a>
<\/img><\/a>
<\/img><\/a>
<\/img><\/a>\n<\/div>\n
<\/p>\n","protected":false},"excerpt":{"rendered":"